Overview
RNXT market data
Price History
RNXT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.32 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.93 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.70 – $1.45 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $40.9 · P/B 5.68 · P/S 27.45.
Company News
8-K filing — RenovoRx, Inc. (RNXT)SEC EDGAR · Jul 2, 2026, 12:30 PM
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should KnowBenzinga · Jun 1, 2026, 12:43 PM
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14Benzinga · Jun 1, 2026, 10:25 AM
RenovoRx Announces FDA Orphan Drug Designation Of Oxaliplatin For The Treatment Of Pancreatic CancerBenzinga · May 28, 2026, 12:45 PM
RenovoRx Announces Online Publication Of Abstract From Pharmacokinetic And Pharmacodynamic Sub-Study Of Ongoing Phase III TIGeR-PaC Clinical Trial In Connection With 2026 ASCO Annual MeetingBenzinga · May 26, 2026, 12:41 PM
RenovoRx Reports Q1 2026 Results: Full Earnings Call TranscriptBenzinga · May 14, 2026, 9:04 PM
RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.Benzinga · May 14, 2026, 8:13 PM
RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.Benzinga · May 14, 2026, 8:12 PM
Earnings Scheduled For May 14, 2026Benzinga · May 14, 2026, 11:11 AM